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Leukemias are monoclonal diseases that arise from cells in the hematopoietic stem and
progenitor cell compartment. Consistent with emerging models of carcinogenesis,
leukemogenesis is an evolutionary process that involves multiple independent genetic and
epigenetic events. Over the last half-century a predominant paradigm has emerged to describe
leukemia developing secondary to alkylating drug therapy or exposure to benzene in which
progressive dysplastic changes, accompanied by a distinct pattern of clonal cytogenetic
abnormalities, give rise to acute myelogenous leukemia. Characterization of these clonal
chromosomal aberrations, together with observed alterations in other growth-promoting genes,
provides a useful framework for studying chemical leukemogenesis and for use in understanding
the origins and development of leukemia in general. Environ Health Perspect 104(Suppl
6):1239-1 246 (1996)
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Process of Leukemogenesis
Leukemias are monoclonal diseases that
originate from individual cells in the bone
marrow. Like other cancers, leukemias
often exhibit a progression in their natural
history from cells that possess a phenotype
exhibiting some remnant of normal differ-
entiation to the progressive loss ofmatura-
tion ability and the development of an
aggressive undifferentiated malignant phe-
notype (1). A common characteristic of
malignant neoplasms, including leukemias,
is abnormal regulation of cell growth. A
particular challenge to understanding the
role of altered regulation of cell growth in
the development ofleukemia is that differ-
ences in the behavior between normal and
malignant hematopoietic cells are often
subtle. For example, normal hematopoi-
etic progenitor cells possess some charac-
teristics common to malignant cells,
among them: the ability to proliferate, sur-
vive intravascular transit, and transmigrate
into tissues, and the ability to grow in
semisolid media. On the other hand,
leukemic cells often do not exhibit total
growth-factor independence when first
introduced into culture.
Consistent with present models for the
origin and progression of neoplasia,
leukemia development has long been
thought to be a multistep process. Foulds
first proposed a multistep progression in
which a normal cell must pass through a
number of distinct intermediate stages
before a frank malignancy develops (2,3).
Since that time, a variety ofindependent
observations have emerged to support the
conclusion that cancer in general is an evo-
lutionary process in which multiple events
involving independent genetic alterations
in protooncogenes or suppressor genes
together with epigenetic or environmental
factors contribute to the development of
the full malignant phenotype (4,5). The
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best understood example ofcarcinogenesis
in a normal, rapidly proliferating tissue is
carcinoma ofthe colon, in which it appears
that as many as five independent genetic
and epigenetic changes may be required
for the progression of a normal epithelial
cell to a carcinoma cell (6,7) (Figure 1).
This model is based on the seminal obser-
vation by Vogelstein et al. that the inci-
dence of ras-gene mutations increased
dramatically as a function of the size and
malignant phenotype of the tumor and
that four molecular alterations accumu-
lated in a manner that paralleled the clini-
cal and histopathological progression of
the tumor (7). In addition to illustrating
the multifactorial nature of cancer devel-
opment, these correlative studies reveal
that the precise sequence ofevents is not a
constant but that individual tumors can
vary in their evolution.
Regulation of Hematopoiesis
A great deal ofevidence suggests that proto-
oncogenes and other growth-promoting
genes such as those encoding for cytokines
or their receptors play an important role in
carcinogenesis and malignant transforma-
tion. Recent advances in cell and molecular
biology have revolutionized our under-
standing of the regulation of growth in
normal hematopoiesis. Therefore, a brief
summary of the functions ofcytokines in
regulating normal hematopoiesis provides a
logical foundation for a discussion of the
mechanisms ofaltered cell growth and dif-
ferentiation occurring in leukemogenesis.
Three fundamental cellular processes that
define hematopoietic cells are survival, pro-
liferation, and differentiation. The survival
and proliferation ofhematopoietic progen-
itor cells (HPC) are controlled by multiple
growth factors or cytokines with overlap-
ping functions that act individually or in
combination to regulate hematopoiesis (8).
Recent studies support the conclusion that
either interleukin-3 (IL-3) or granulo-
cyte/macrophage-colony-stimulating factor
(GM-CSF) are required to sustain the via-
bility of stem cells or early HPC. Early
HPC can also be recruited into active cycle
in response to these same cytokines or a sec-
ond stimulus such as c-kit ligand (CKL),
IL-6, or granulocyte colony-stimulating fac-
tor (G-CSF) (9-11). Later committed
progenitor cells are controlled by lineage-
specific cytokines such as erythropoietin,
macrophage colony-stimulating factor
(M-CSF), G-CSF, and IL-5. Populations of
Environmental Health Perspectives - Vol 104, Supplement 6 * December 1996 1239IRONS AND STILLMAN
DNA
hypomethylation
12p
activation
K-ras
18q 17p
loss loss
DCC p53
Normal Hyperplastic Early Intermediate Late
epithelium epithelium adenoma adenoma adenoma Carcinoma
Figure 1. Changes that occur during the evolution of a typical colorectal carcinoma. Schematic representation of a
model of tumor progression in which independent steps are required, leading to the activation of at least one
protooncogene coupled with the successive loss of several tumor suppressor genes. Adapted from Varmus and
Weinberg (6).
early HPC responding to IL-3 and
GM-CSF exhibit extensive overlap.
Although IL-3 or GM-CSF is required to
sustain survival ofearly dormant progenitor
cells (12), IL-3 apparently stimulates cells at
an earlier stage of differentiation than
GM-CSF (13). Early IL-3 responding pop-
ulations support the development ofT- and
B- lymphocyte progeny as well as myeloid
and erythroid lineages (14-16). Because IL-
3 responsiveness is a characteristic of HPC
at multiple levels ofdifferentiation, HPC
responsive to GM-CSF may represent a
subpopulation of multipotential cells that
respond to IL-3 (17). The processes that
govern differentiation of HPC are less well
understood and are thought by many to be
governed via stochastic mechanisms.
Nevertheless, it is reasonable to infer that
differentiation and lineage commitment
are at least indirectly influenced by envi-
ronmental factors (e.g., cytokines). The
role of altered regulation of cytokine
expression/response in leukemogenesis is
complex, with consistent enhanced expres-
sion ofGM-CSF or IL-3, resulting in pro-
found myelodysplastic changes (18-20).
Altered regulation ofclonogenic response to
GM-CSF features prominently in both
human and murine myeloproliferative dis-
orders and is a frequent early observation in
the development of acute myelogenous
leukemia (AML) (5,21). Repeated expo-
sure of mice to benzene in vivo enhances
GM-CSF response (22), and chronic
exposure to high concentrations induces a
persistent myeloproliferative disorder
(23,24). Moreover, the benzene metabo-
lite, hydroquinone, selectively enhances
clonogenic response to GM-CSF in
murine and human bone marrow cells
(25-27). To date, alterations in expression
ofM-CSF/FMS have not yet been shown to
result in abnormal myeloid proliferation.
Relationship between
Leukemia, Preleukemia, and
Myelodysplastic Syndrome
It is generally recognized that chromoso-
mal aberrations or deletions can alter the
regulation and function of protooncogenes
and other growth-promoting genes. This,
together with our growing knowledge of
the function and role of cytokines, their
receptors, protooncogenes, and suppressor
genes, provides a useful framework for
analysis ofthe respective roles ofaltered cell
growth and differentiation in chemical
leukemogenesis. To this end, an impressive
literature exists that describes the natural
history ofleukemia secondary to alkylating
drug or occupational exposure in which the
development ofAML is a) preceded by pro-
gressive dysplastic or "preleukemic" changes,
and b) accompanied by a distinct pattern of
clonal cytogenetic abnormalities.
The concept ofpreleukemia originated
around the turn of the century with the
observation that AML could be preceded by
a cytopenic dysplasia involving one or more
hematopoietic cell lines (28). However,
preleukemia was not generally accepted as a
clinical entity until thewidespread introduc-
tion ofradiation and chemotherapy in the
treatment ofother types of cancer. It is now
widely recognized that persistent cytope-
nias and other blood dyscrasias, including
dyserythropoiesis, dysgranulopoiesis, and
dysmegakaryopoiesis, frequently precede
the onset ofleukemia in patients develop-
ing AML secondary to exposure to benzene
or alkylating agents (1,29-32). Over the
past decade the term preleukemia has been
largely supplanted by the more functional
classification of the myelodysplastic syn-
dromes (MDS) by the fast atom bombard-
ment (FAB) (33). Differences in growth
and differentiation between MDS and
AML find analogy in the progression of
solid tissue tumors from metaplasia and
dysplasia to carcinoma. This observation,
together with the frequent progression of
secondary s-MDS to frank AML, leads to
the inescapable conclusion that MDS and
AML should be considered a single disease
continuum when viewed in the context of
chemical leukemogenesis.
As a secondary malignancy, AML
clearly dominates the leukemia literature.
At present, the world literature contains
approximately 38,000 cases of individuals
treated with alkylating agents or radiation
for primary malignancies or immune disor-
ders that have been followed for develop-
ment ofsecondary malignancies, the most
prominent ofwhich is AML. These typi-
cally involve MI, M2, M4, M6, but not
M3 or M5 subtypes ofAML, based on the
FAB classification system (34,35). From
these studies at least 1322 cases ofAML
and 320 cases ofMDS have been reported
(29,30,36-57). If one includes all cases
attributed to solvent exposure in general or
benzene specifically, whether anecdotal or
reported in case-control or cohort studies,
the total number of secondary leukemias
approaches 2100, over 96% ofwhich are
MDS/AML (44,58-70). The frequency of
secondary AML/MDS varies markedly
depending on individual therapeutic regi-
men but historically has ranged between
0.6 and 17%, with relative risks averaging
about 100-fold (range 9-320 X). These
studies establish a consistent and very strong
pattern in which the development ofAML
is preceded by a period ofpreleukemia in 33
to 80% ofthe cases and is accompanied by
clonal cytogenetic abnormalities involving
loss ofall or part ofchromosomes 5 and 7
(Table 1). On average the frequency ofdele-
tions or loss of chromosomes 5 and 7 in
studies of patients who develop MDS or
AML after antineoplastic therapy ranges
between 85 and 95% (71-76). The same
cytogenetic abnormalities occur much less
frequently in de novoAML: in 660 de novo
cases chromosomes 5 and 7 were observed
in 4.2 and 4.4%, respectively, and simulta-
neously in 3.2% (77,78). Consistent with
the evolution of s-AML described previ-
ously, most patients presenting with clonal
chromosomal aberrations involving the loss
ofall or part ofchromosomes 5 or 7 exhibit
a preleukemic phase prior to the onset of
AML (79). Analysis ofthe specific pattern
ofcytogenetic involvement in AML devel-
oping secondary to benzene exposure is
complicated by the ambiguities commonly
associated with the characterization of
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Table 1. Cytogenetic characteristics of secondary acute myelogenous leukemia.
Clonal aberrations -5, -7, 5q-, 7q-or both
Denovo Secondary Denovo Secondary
Study AML, % AML, % AML, % AML, %
FIWCL(77) 54 73 12 48
Le Beau et al. (73) 56 97 16 87
Rowley et al. (72) - 96 - 92
Rowley et al. (71) - 100 - 90
Pedersen-Bjergaard et al. (121) - 86 - 89
Wald and Conner(122) - 87 - 80
Mitelman etal. (59) 24 83 12 84
Golomb et al. (60) - 75 - 67
Fagioli etal. (61) 29 88 20 46
exposure in occupational and retrospective
studies. Issues related to the specificity and
intensity of benzene exposure notwith-
standing, the classic pattern involving a
high frequency of loss of all or part of
chromosomes 5 and/or 7 is also observed
in studies of patients occupationally
exposed to benzene specifically or solvents
among which benzene is the only recog-
nized leukemogen (58-61,63,65,80,81).
The consistency of this pattern is all the
more impressive when one considers that
the association between exposure and cyto-
genetic abnormalities in occupational
studies is invariably diluted; i.e., studies
providing the greatest detail on cytogenetic
abnormalities are weakest in the characteri-
zation ofexposure criteria. Independently,
recent studies ofperipheral lymphocytes in
benzene-exposed individuals in China have
shown that benzene exposure induces aneu-
ploidy of C-group chromosomes, with an
especially strong effect on chromosome 7.
Both hyper- and hypodiploidy ofchromo-
some 7 occurred more frequently in ben-
zene-exposed workers than in matched
controls (82). Other nonrandom clonal
chromosomal abnormalities, such as +8 or
+21, have been observed to be increased in
either exposed or nonexposed populations,
depending on the study (58-60,62,81).
These observations suggest that although
some chromosomes other than 5 or 7 can
be involved in the pathogenesis ofAML
secondary to exposure to benzene or
chemotherapeutic alkylating agents, they
are not useful in discriminating between
de novo and s-AML (83). More recently, a
distinct pattern of secondary AML has
been observed following therapywith drugs
targeting DNA-topoisomerase II. The pat-
tern ofAML developing as a consequence
of exposure to these agents, examples of
which include etoposide and teniposide,
includes the notable absence of a
preleukemic phase, frequent presentation of
an M3 subtype, and balanced chromosome
aberrations involving bands 1 1q23 and
21q22 (84). Although it has been hypothe-
sized that benzene metabolites may inter-
fere with topoisomerase II (85), the pattern
ofleukemias and chromosomal aberrations
typically associated with inhibition ofthis
enzyme has yet to be observed in occupa-
tionallyexposedpopulations.
5-/5q-: A Model forthe
Pathogenesis of Leukemia
The pattern of reoccurring chromosomal
abnormalities associated with the develop-
ment ofleukemia can be used as a guide in
understanding the etiology and pathogenesis
of these diseases. A number of gene loci
have been mapped to chromosome 7; how-
ever, their function(s) remains largely
unknown (86). However, recent progress in
the mapping ofgenes to the region ofchro-
mosome 5 involved in s-MDS/AML, pro-
vides a logical starting point for a discussion
ofpossible mechanisms ofleukemogenesis.
Deletions ofall or part ofchromosmes 5 or
7 are the earliest clonal alterations that have
been detected in MDS/AML. Deletions
associated with 5q- in s-MDS/AML are
usually interstitial without translocation of
the deleted material (73,87). The variabil-
ity of the breakpoints, together with
identification ofthe critical region (5q31),
suggests that the relevant genetic event may
be the deletion ofa critical gene sequence
rather than consistent juxtaposition of
DNA sequences that may occur in chromo-
some translocation (Figure 2) (73). A clus-
ter of genes involved in the regulation of
hematopoiesis is located at q31 on chromo-
some 5 (Figure 3). These include
GM-CSF, IL-3, IL-4, IL-5, CD14 (which
encodes a myeloid-specific surface molecule
that has structural characteristics ofa recep-
tor), and early growth response 1 (EGRI)
(an EGRgene withfos-like properties) (88).
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Figure 2. Fragile site on chromosome 5 associated with region of critical deletion in patients with t-AML. Vertical
bars indicate deleted segments and numbers indicate number of patients with same deletion. Dashed bars indi-
cate smallest overlapping region of 5q31. Reproduced from Rowley and Le Beau (88), with permission.
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Figure 3. Genetic map of genes located in and adjacent to the 5q31- critical region deleted in patients with
t-AML. Modified from Rowley and Le Beau (88). Abbreviations: 32AR, P2-adrenergic receptor; ECGF, endothelial
cell growth factor; PDGFR, platelet-derived growth factor receptor.
There is no evidence for homozygous dele-
tion of any ofthese genes in AML, such as
has been described for retinoblastoma in
which the absence of one allele of
retinoblastoma gene is followed by a sec-
ond somatic mutation, resulting in loss of
both copies of the gene (89). The most
consistent deletion associated with 5q31-
appears to involve the loss of one allele
encoding either GM-CSF or EGR1 (88).
Close to, but lying outside of, the critical
region is the protooncogene, c-fins, the
receptor for M-CSF that acts exclusively on
cells of monomacrophage lineage (90).
Ostensibly, a critical role for c-fins in the
development of AML is an attractive
hypothesis in that it encodes a cytokine
receptor. However, the weight of evidence
suggests that c-fins is probably not involved
in early events in AML development.
M-CSF and c-fins lie outside the critical
deletion region at 5q31 (88), and although
FMS expression can be detected on
leukemia cells in approximately 30% of
AMLs, abnormal myeloid proliferation has
yet to be demonstrated as a result of inap-
propriate expression of M-CSF or FMS
(5). Nevertheless, the incidence of point
mutations in the c-fns gene in AML or
MDS has been reported to be 13% in one
series, suggesting that subtle changes in
c-fins expression may contribute in some
way to the development of the malignant
phenotype (91).
At present, there are at least two molec-
ular hypotheses for the role of 5q- abnor-
malities in the development ofMDS/AML.
First is the loss of a single allele of a hereto-
fore unidentified tumor suppressor gene
that results in production of a nonfunc-
tional protein; this would be analogous to
the inactivation ofp53 by point mutation.
The second hypothesis is that loss of a sin-
gle allele leads to altered gene dosage and a
reduction in the level of gene product,
such as GM-CSF. A third possibility is
that involvement of intact genes adjacent
to the interstitial deletion cannot at this
time be entirely excluded since their func-
tion could ostensibly be influenced by the
structural changes that have occurred in
the chromosome.
In addition to early involvement of
genes on chromosome 5, a growing num-
ber ofprotooncogenes have been reported
to undergo structural or functional alter-
ations in AML with widely differing fre-
quency. These have been the subject of a
number ofreviews (5,92-94). To date, no
single or consistent pattern ofprotoonco-
gene involvement has been associated with
AML development, suggesting that multi-
ple genes may interact via different path-
ways in the evolution of the disease. This
discussion will focus only on a small num-
ber of these genes. The human ras genes
encode p2l proteins that appear to play an
important role as second messengers in
tyrosine kinase receptor-mediated signal
transduction (95). It has been hypothe-
sized that ras mutations may feature
prominently in the development ofs-AML
(96). However, what role ras mutations
play in the development ofeither de novo
or s-AML remains uncertain. In a large
number ofstudies, ras protooncogene acti-
vation, principally N-RAS, has been vari-
ously reported to occur in about 25% of
cases of de novo AML (92,95). However,
clonal chromosomal aberrations have been
demonstrated to precede ras involvement
in the evolution ofthe disease (97,98) and,
when identified, ras mutations tend to be
present only in subclones of the leukemic
cells (97,99). To date, RAS involvement
has not proven to be either a prognostic
indicator or to correlate with FAB subtype.
From these studies it appears that ras
mutation is an unlikely early event in AML
and is insufficient to cause the disease.
However, ras activation can occur at a
number of stages in the development of
AML and it cannot be excluded that RAS
may play a role in the evolution or progres-
sion of at least some cases ofAML (100).
The p53 gene encodes a phosphoprotein
nuclear transcription factor that is spatially
regulated within the cell during the cell
cycle. The wild-type protein is known to
limit cell growth apparently by two inde-
pendent mechanisms: mediating apoptosis
and as a checkpoint, regulating the length
of GJ (101). Often referred to as a tumor
suppressor gene, inactivation ofp53 is an
important event in the transformation of
many tumors and is the most frequently
encountered gene mutation in human
cancer (102). Inactivation of p53 is
involved in the progression to blast crisis in
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20 to 30% ofchronic myelogenous leukemia
(CML) cases, but it is only encountered in a
few percent of MDS/AML cases (103).
Within this small subset ofAMLs, p53
inactivation is a late event and is apparently
associated with loss ofa differentiated cell
phenotype, aggressive course, and a poor
prognosis. The retinoblastoma (Rb) gene
was the first identified tumor suppressor
gene and like p53 encodes a phosphonuclear
protein that is involved in regulating critical
events in the cell cycle (104,105). Absent or
decreased expression of Rb protein is
observed in approximately 30% ofAML
cases and is associated with a particularly
dismal response to therapy (106,107).
A Model for Leukemogenesis
Up to this point the discussion has focused
exclusively on the role of clonal hemato-
poietic stem and progenitor cell abnormali-
ties in the development and evolution of
MDS/AML. Another hypothesis has been
proposed in which altered growth factor
production by fibroblasts, endothelial cells,
and macrophages may feature prominently
in the development ofleukemias (108). As
the basis for a stand-alone theory ofleuke-
mogenesis, each of these alternatives pos-
sesses individual strengths and weaknesses.
A diverse set ofobservations argues persua-
sively that the ultimate clonal derivation of
most cases ofAML and MDS are HPC
essentially restricted to the myeloid lineage
(109-112). Superficially, a clonal lesion
would appear to be incompatible with the
notion that persistent and progressive
myeloproliferative disease could arise as a
consequence ofaltered microenvironmen-
tal influences that are ostensibly indepen-
dent and oligoclonal. On the other hand,
how allelic deletion ofa cytokine gene such
as GM-CSF in a single clone ofprogenitor
cells can predispose to a series ofevents that
utlimately leads to AML remains a niggling
enigma. The basis for the argument for a
stromal origin is that multiple peripheral
cytopenias and dysplasias are the rule rather
17p
5q- loss
Enhanced loss Increased Activation p53/Rb
GM-CSF GM-CSF stromal N-ras activation
response EGR1? GM-CSF c-fms c-myc
Altered Apoptosis/
Normal recruitment HPC turnover MDS Decreased
hematopoiesis . j cytokine AML
Hyperplasia Metaplasia Dysplasia dependence
Figure 4. Hypothetical model forthe evolution of secondary leukemia involving 5q-. Schematic representation of a
model of abnormal myeloproliferative progression in which early events, including alterations in cytokine response
and loss of heterozygosity (5q-), are followed by activation of at least one protooncogene coupled with the suc-
cessive loss of a tumor suppressor gene.
than the exception in the evolution of
s-AML, and abnormal cytokine production
is frequently encountered in cases of
MDS/AML (113-116).
Alternatively, one can propose an
integrative model ofleukemogenesis that is
compatible with both donal and microenvi-
ronmental involvement in the development
and progression ofthese myeloproliferative
disorders. In hematopoiesis, there is con-
siderable evidence that cell viability and
cell growth are functions that can be disso-
ciated (117). Raza et al. (118,119) have
recently reported an increase in both cell
turnover and apoptosis in bone marrow of
patients with MDS relative to normal bone
marrow that is in sharp contrast to AML,
in which proliferation is high but the fre-
quency ofapoptotic cells is low. A chromo-
somal aberration in an early progenitor cell
could result in allelic deletion of one
GM-CSF gene, resulting in a commensu-
rate decrease in intracellular GM-CSF.
Using antisense technology, Pech and co-
workers provide evidence that low-level
autocrine regulation ofGM-CSF may reg-
ulate survival in early progenitor cells inde-
pendent of exogenous GM-CSF that is
associated with proliferation (120). Ifintra-
cellular GM-CSF were insufficient to
suppress apoptosis in maturing cells ofthe
affected clone, a corresponding increase in
exogenous GM-CSF occurring in phys-
iologic response to increased apoptosis
would drive cell proliferation, leading to an
increase in overall cell turnover in the
affected clone. This model is consistent with
the regulatory paradox in MDS in which
bone marrow hyperplasia is accompanied by
ineffective hematopoiesis and cytopenias.
Subsequent events involving genes linked
directly or indirectly to cell survival and
maturation (e.g., ras, p53, or Rb) could
enable the escape ofthe subclone from the
apoptotic treadmill and development of a
frankAML (Figure 4).
This model is only one possible explana-
tion for the origins and progression of
leukemia that is compatible with roles for
both clonal and microenvironmental events.
The earliest observations associated with the
development ofMDS/AML suggest that a
relatively small number ofalternative events
predispose the development ofleukemia.
These most likely involve a clonal chromo-
somal abnormality together with altered
regulation ofcytokine response. However,
the diversity ofgene involvement in later
stages ofAML progression is consistent
with an emerging pattern in cancer biology
in which multiple alternative genetic path-
ways converge in the development of a
specific tumor type.
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